Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences Inc AURA
$6.00
▼ -2.44%
($-0.15)
Open
$6.18
Prev Close
$6.15
Day Range
$5.99 – $6.18
52W Range
$4.73 – $9.54
Market Cap
$622.23M
Beta
0.41
EPS (TTM)
$-1.76
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-29 |
| Shares Out. | 103,440,000 |
| Website | aurabiosciences.com/ ↗ |
| Phone | 16175008864 |
| Employees | 113 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$45.6M |
| Free Cash Flow | -$103.4M |
| Total Assets | $348.1M |
| Total Liabilities | $32.9M |
| Equity | $315.3M |
About Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Aura Biosciences Inc is a publicly traded company under the ticker symbol AURA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)